DaVita Inc. (DVA) Earnings Call Transcript & Summary

August 3, 2023

New York Stock Exchange US Health Care Health Care Providers and Services earnings 38 min

Earnings Call Speaker Segments

Nic Eliason

executive
#1

Thanks for joining us for the conference call covering quarter two, and we're glad you continue to follow what's happening at this company. My name is Nic Eliason, and I serve as Group Vice President of Investor Relations. With me on the line are Javier Rodriguez, who is our CEO, and Joel Ackerman, our CFO. Before we go further, be aware that statements we might make today could be forward-looking, as that term is defined under federal securities laws. Known and unknown risks and uncertainties apply to each of those statements, and those factors might cause results in reality to differ in a material way from what the forward-looking statements describe. If you want more information about those risks and uncertainties, take a look at the press release on our quarter two earnings along with our SEC filings, which include the most recent annual report on Form 10-K, every quarterly report on Form 10-Q filed afterward, and any other documents we subsequently submit to the SEC. What we say about the future reflects what we know right now, and we have neither the intention nor any obligation to revise those statements, unless the law demands it. We also want to point out that certain non-GAAP financial measures will come up in today's discussion. You can find a reconciliation between those non-GAAP measures and the closest comparable GAAP measures in the earnings press release we furnished to the SEC, which is also posted on our website. At this point, I'll hand things over to Javier Rodriguez.

Javier Rodriguez

executive
#2

Thanks, Nic, and I appreciate everyone taking the time to be with us on today's call. I hope you're all enjoying a summer that's both safe and happy. Here at DaVita, our attention has been on innovating and getting better continuously so that patients receive care of the highest quality. Alongside those efforts, we've been pushing operational gains throughout the company. The results we posted for the second quarter show solid momentum behind those initiatives, which positions us well to produce robust clinical outcomes and financial performance for the full year. Today I'll walk through the second quarter results, share some thoughts on the industry landscape and what drives long-term performance, and then update our guidance for the full year. Before diving into second quarter specifics, I want to pause and mark a milestone in both clinical care and technology; during our February call, we talked about rolling out our next-generation clinical IT system, known as Center Without Walls, or CWOW. I'm pleased to share that following 5 years of development, CWOW is now live across each of the roughly 2,700 clinics we operate throughout the United States. This cloud-based, patient-centric system consolidates and takes the place of four legacy systems, and it's built to enable information to flow seamlessly across all of our centers in every modality; that covers real-time clinical dashboards, sharing of data with our physicians in Integrated Kidney Care platforms, and notifications like critical lab alerts; to make it easy to use, it includes wrist bands for fast teammate log-in, better ability to track and reschedule mistreatment, improved real-time documentation, and consolidated reporting for more streamlined analysis. And while these immediate benefits have us excited, the biggest enhancement is the state-of-the-art data structure and platform that lets us build additional capabilities on top, including artificial intelligence, to move care delivery forward in the years to come. With this groundbreaking platform, our clinicians can get the right information at the right time in the right place. Turning to our financial performance; during the second quarter, adjusted operating income came in at $432 million and adjusted earnings per share were $2.08; improvements across our financial trilogy of treatment volume, revenue per treatment, and patient care costs drove these results. I'll go into each of these a little more; on volume, we recorded our second quarter in a row of gains in census and treatments per day. That's encouraging, since it stems from a better macro environment and progress on our operating initiatives. We're tracking close to the upper end of our initial volume range of down 3% to flat year-over-year. Should these trends hold, we'd expect to see volume growth in 2024. Moving to revenue and revenue per treatment. Revenue per treatment was especially strong this quarter. The main drivers were typical seasonal factors from patients hitting their co-pays and deductibles, plus normal expected rate increases and better mix, including Medicare Advantage. On top of the RPT increase, we're seeing gains from money we've put into our revenue cycle capabilities; those investments drove up cash collections and brought our DSO down. I'm enthusiastic about what we've been doing in these areas — it's a solid illustration of how we keep making operations better. And lastly, patient care costs came in better this quarter, just as we anticipated. Base wage increases are still far above where they sat historically before the pandemic, but other expenses, such as contract labor and pharmaceuticals, keep falling. Elevated training costs partly offset that benefit. Our clinic staffing is in a far stronger spot than it was a year ago, yet turnover among facility teammates remains above average. Because of that, we no longer anticipate any gain in training productivity over this year's back half. Stepping away from the latest results, I'd like to share a few thoughts on the wider industry picture and how we're working to improve performance ahead. Starting with reimbursement rates, CMS' proposed rule updating the ESRD Prospective Payment System for 2024 disappoints us. To be specific, the proposed rate increase doesn't cover anticipated cost inflation in 2024, and it neglects to account for the acknowledged miss in the inflation forecast versus the actual wage and inflation growth of the prior two years. The Kidney Care community will keep pushing for an adjustment mechanism that reconciles these forecasters, much like the one that exists today for skilled nursing facilities. Facing ongoing cost inflation, we're maintaining our history of innovation throughout every part of our cost structure. Most recently, we consolidated parts of our facility footprint and lowered pharmaceutical costs by converting to MIRCERA for anemia management. These programs are tracking right where we expected. Looking ahead, we'll keep driving cost efficiencies across the P&L. Through those efforts and further gains in our volume trends, our target remains 3% to 7% long-term growth of our enterprise adjusted operating income. Turning to the rest of the year, because of our second-quarter progress, we're revising our adjusted operating income range of $1.475 billion to $1.625 billion to a new range of $1.565 billion to $1.675 billion. We're also updating our adjusted earnings per share range of $6.20 to $7.30 to a new range of $7 to $7.80. How we perform against this guidance will still hinge heavily on momentum in patient census trends, our capacity to manage patient care costs within the broader labor environment, and sustained improvement in revenue cycle management. I'll now hand the call to Joel to discuss financial performance and outlook in more detail.

Joel Ackerman

executive
#3

Thank you, Javier. I'll go through several elements that fueled our robust results in Q2, beginning with treatment volume; during the second quarter, U.S. dialysis treatments per day rose roughly 0.3% on a sequential basis. That reflects ongoing census growth during Q2, which was driven by a rise in new-to-dialysis admissions. Mortality is still above what we saw before COVID, yet it landed below Q1 and matched what we had expected for the quarter. Our mistreatment rate remains elevated compared with historical norms. Revenue per treatment climbed $10.59 from Q1. About half of that gain stemmed from seasonality, mainly because patient responsibility amounts were higher in the first quarter. Roughly $2 came from the usual anticipated rate increases along with ongoing improvements in patient mix. Another approximately $2 resulted from robust cash collections during Q2. As Javier mentioned, we've been putting money into upgrades to our revenue cycle management systems and processes, and we're starting to realize the payoff from that work in both RPT and DSOs; we had expected these gains, though they arrived sooner than we had projected. We believe these benefits will carry through the back half of the year and beyond. Consequently, we now expect year-over-year RPT growth of 2.5% to 3%. On a non-GAAP basis, patient care cost per treatment fell 1.5% sequentially. Although base wage increases stay elevated, we've managed to wind down most of the temporary compensation measures we depended on throughout 2022. By the close of Q2, contract labor had come back to pre-pandemic levels. Operating income from our Integrated Kidney Care business was roughly even with Q1. The quarter gained from favorable prior period developments in our special needs plans plus the timing of expenses that got pushed to later in the year. For the whole year, we now anticipate IKC adjusted operating income to be approximately flat against the 2022 operating income loss of $125 million. Turning to our clinic footprint in Q2, we shut or consolidated 16 centers across the U.S., which brings our year-to-date U.S. closures to 36. We'll keep evaluating additional facility consolidation and closures over the back half of the year. On capital structure, we finished the quarter with a leverage ratio of about 3.7x EBITDA and didn't buy back any shares in the second quarter. Our capital allocation approach stays centered on capital efficient growth, a target leverage ratio of 3x to 3.5x EBITDA, and returning excess cash flow to investors via share buybacks. Because of our raised guidance for the rest of the year, we've gained better visibility into returning our leverage level to within our target range; that wraps up my prepared remarks for today. Operator, please open the call for Q&A.

Joanna Gajuk

analyst
#4

I'm actually Joanna, sitting in for Kevin today. Thanks for the detail on the revenue-per-treatment split and what's driving it, including that very strong showing — I appreciate the commentary. I'd expect, I imagine, growth to be quicker this year. So let me dig into the components, since a better payer mix was one of the drivers you named. Could you discuss commercial pricing specifically and the rate increases you're securing this year? And any signals about how that's shaping up for next year? Because I think that may be one spot — you also brought up Medicare rates being below cost inflation. So is commercial pricing, I suppose, performing better?

Javier Rodriguez

executive
#5

Yes. Thanks for asking, Joanna. I'll kick things off, and Joel, feel free to add anything important I leave out. Our private pay mix remains solid. It rose 20 bps, and we keep seeing that patients paying privately truly value their coverage. On rate increases, a quick reminder: the majority of our contracts run multiple years, so in a typical year we aren't renegotiating very many of them. There isn't much to highlight there. Our rate per treatment increases match what we expected. So is there some other aspect of your question I didn't address, Joanna?

Joanna Gajuk

analyst
#6

No, that covered it. But I suppose, if I may, I'd like to ask something that builds on the same subject — specifically the Marietta case. I believe we discussed this previously, and bipartisan backing for a legislative remedy still exists. So could you share any new information on that front? And on that same subject, when it comes to pricing — commercial pricing — are employers taking this court ruling and using it as a way to narrow their networks? Or perhaps they're raising it during rate discussions — bringing it into the conversation when rates are being negotiated?

Javier Rodriguez

executive
#7

Certainly. Let me widen the frame a bit, because not everyone is following every detail of the Marietta situation. I think the cleanest approach is for me to separate it into the things we're certain about and the things we aren't. I'll begin with what's certain. When we examine our claims for the year so far, the picture looks largely the same as in earlier years. So volume isn't really the issue; however, we've gained a clearer understanding of the ways employers alter benefits and steer members in a misleading manner regarding how that's carried out. And we have no desire to go along with that kind of bad conduct. So here's what we've put in place: a verification step at the point of admission, and should an employer remove a network dialysis benefit from its members' coverage, we retain the right to block that plan from accessing our centers. On top of that, there remains a great deal of interest — from both sides of the aisle — in ensuring that lawmakers safeguard our patients. Those are the certainties. As for the uncertainties: we don't know how many employer groups might be weighing the removal of dialysis from their networks going forward; nor do we know whether or when legislation will be brought forward by members of Congress, or what score the CBO would give it. The final piece of what you asked was whether payers are leveraging this somehow, and it hasn't surfaced in a single negotiation, because ultimately this is a matter between the employer deciding what to do with its plan, rather than anything the payer does with the provider. Both the provider and the payer see value in the network. Does that answer your question, Joanna?

Joanna Gajuk

analyst
#8

Yeah, that's clear. No, that's completely clear, and I'm grateful for that. So regarding the situation in Congress and the score, is there anything pointing to what we could expect to hear on this? Or is that simply not something those of us on the outside can foresee?

Javier Rodriguez

executive
#9

Right. We can't foresee anything from where we sit. That's up to policymakers, champions, and how things play out in Washington, D.C.

Joanna Gajuk

analyst
#10

Wonderful; and if I could just ask about the increase to guidance, correct, it seems as though there's been some enhancement in the pricing rate and then, I suppose, contract labor. It seems as though that's improved. Should that be how to describe the guidance increase, the $70 million of the operating income — adjusted operating income guidance?

Joel Ackerman

executive
#11

Yeah, Joanna, if I were going to sort of break down for you the components of what produced $70 million of higher guidance that's middle of the range — to middle of the range on OI. I'd say roughly half is the RPT, as you pointed out, the remaining half is volume. We experienced stronger admissions this quarter and the character of volume is that it's cumulative. It's never going to truly take effect, in any single quarter to that large a degree. But as it builds up stronger in Q1, stronger in Q2, and we observe it better in the back half of the year, for the full year, we believe that will account for about half of the $70 million beat. Contract labor, it keeps getting better, but it's now pretty much aligned with what we had anticipated. And as we stated in the prepared remarks, it's really returned to pre-COVID levels. And ideally, it won't be much of a subject going forward.

Andrew Mok

analyst
#12

Thanks for all the detail on how RPT improved sequentially — I just have a few quick follow-ups on that. One, does the seasonal pattern match what we've typically seen? Or is there something in the patient benefit design making seasonality sharper this year? Also, could you elaborate a little on the reasons cash collections are coming in stronger?

Joel Ackerman

executive
#13

Sure, Andrew — appreciate it. As far as seasonality goes, no, it came in slightly above $5, on a per-treatment basis, and that's right where it has landed historically. On the collections side, here's the thing: we've put money into our processes and our technology so we can obtain better information and pass better information along to the health plans — covering everything from prior authorizations to other required data to claim submissions — and that applies to both how good the data is and how timely it is. What that means is faster payment, which explains why DSOs declined in the prior quarter and once more in this one. On top of that, we're bringing in more, and that is what's pushing the RPT increase. From where we sit, the key point is that this isn't a onetime thing. The changes we've made are fundamental, and our view is they'll persist.

Andrew Mok

analyst
#14

Great. Thanks for that detail. Then, to follow up: with the OI guidance up roughly 5% and free cash flow, I believe, up around 10%, could you bridge that gap for us? Also, help us see why the new guide implies better free cash conversion. I think I missed what you said about share repurchase, so I'd love to hear your current thinking on possibly restarting it.

Joel Ackerman

executive
#15

Sure. The main gap between OI and free cash flow comes from DSOs. As those DSOs decline, that will boost free cash flow for the year. On share repurchases, we're where we planned to be. Our leverage was above the target range; I think we were very clear with everyone that we wanted to return to 3.5x or lower. We're progressing well on that. For the quarter we're at 3.7x, and we didn't repurchase any shares. In Q3, we don't anticipate repurchasing any shares. Still, we believe we now have improved visibility to get back to 3.5x or below.

Lisa Clive

analyst
#16

Javier, I apologize if you covered this during your opening remarks — I arrived a few minutes late. Could you share your thoughts on the CMS rate increase, along with the fact that they acknowledged an error in their calculations, and what the likelihood is that we see an improvement there? Also, as we look ahead toward 2025, how would a reasonable rate increase be defined? And what smaller figures ought we realistically to expect?

Javier Rodriguez

executive
#17

Yes. Thank you for asking, Lisa. It's somewhat amusing. I've been with this organization for quite a long while. Questions about the Medicare rate increase rarely came up in the past, so we began wondering why this has become a new pattern; the truth is that the system is very complex, yet it functions reasonably well when the economy is stable. However, when we find ourselves in periods of inflation or instability, it becomes clear that in numerous respects it simply doesn't function. But let me back up. Should you take the time to dig into the methodology, you would ultimately conclude that forecasting it is essentially impossible, since far too many elements are either proprietary, rely on lagged data, or use a benchmark tied to overall health care costs rather than to dialysis, and everything gets weighted and then discounted by some productivity factor. Therefore, the brief response is that it's a large, intricate equation containing certain variables we simply won't be able to see. That's the concise answer; forecasting isn't something we can do. I doubt anyone outside the company could either. Next, regarding what an appropriate increase would be, our position is that we should avoid what we might call winners or losers; we recognize forecasting is hard, but we want a reconciliation tied to real costs. And if an increase surpasses inflation, then a reduction could follow, or the reverse; that's the position we're pushing for. As you're aware, securing funding in Washington, D.C. is extremely tough at present, but we're working to make our argument.

Lisa Clive

analyst
#18

Perhaps we could also briefly discuss what MedPAC does in this context. They serve, in a sense, as Medicare's economic advisor, yet they lack any authority to enforce anything, and I believe there are occasions — certain years — where a significant gap exists between what MedPAC suggests and the actual rate, while this time around, the two were fairly aligned. From where you sit, does your team actually pay attention to the figures MedPAC puts out? It strikes me as something that ought to be a helpful reference point, but frequently it isn't.

Javier Rodriguez

executive
#19

Correct. Their methodology seems somewhat unclear from our vantage point; we attempt to inform and draw attention to the realities of our cost structure. And once more, during stretches of steadiness, it turned out to be, more or less, tolerable and reasonable, but at present the disparity keeps growing and it grows larger with each passing year. So it is genuinely becoming meaningful.

Lisa Clive

analyst
#20

All right, and my final question is this: considering the way that rate hike played out, does that alter your thinking at all regarding certain clinic shutdowns? Since clearly, the concern is always that should Medicare reimbursements fall too far, you wind up with locations scattered around that serve only Medicare patients, and at that point it simply stops making financial sense.

Javier Rodriguez

executive
#21

Yeah. A great many factors feed into whether we shut down a clinic. Specifically, our attention has to stay squarely on caring for patients and ensuring they receive proper treatment; yet economics definitely play a role when you examine them, though continuity of care serves as the initial screening criterion. Next comes whether there's a handy location available for treating that patient, and beyond that, you move into financial considerations like reimbursement rates, lease agreements and similar matters, but we're taking a hard look at our footprint and keep adjusting our size so that we remain deliberate regarding how we allocate resources and capital.

Pito Chickering

analyst
#22

Can you guys hear me now?

Javier Rodriguez

executive
#23

Yes.

Joel Ackerman

executive
#24

Yes, Pito.

Pito Chickering

analyst
#25

Okay. My apologies — I don't know what occurred there. Returning to the subject of treatment growth, before COVID you were adding roughly 4,000 new patients annually, with around 2/3 of them arriving during the first half of the year as nephrologists handed them over, and clearly the remainder came through hospitalizations and began dropping to you folks. So how is that shaping up this year so far against that 4,000 x 2/3 figure? What sort of new patient numbers are you observing right now?

Joel Ackerman

executive
#26

Yes; so Pito, to put it briefly, when you look at admits, we're basically matching pre-COVID levels. What's challenging us is excess mortality. It's still elevated, and because of that we can't yet declare that we'll get back to pre-COVID growth levels. That being said, mortality keeps falling year after year from when COVID began, and it's lower in Q2 than in Q1. So should mortality keep dropping and reach pre-COVID levels, then that arithmetic you described — 4,000 new patients a year — we'd be right back there.

Pito Chickering

analyst
#27

That leads nicely into what I want to ask next, which is about mortality. You mentioned it's been coming down. Can you give us some sense of how fast that decrease is happening? And if it keeps going the way it has over the past three quarters, what kind of path would that put us on?

Joel Ackerman

executive
#28

Yeah. That's a hard thing to analyze, because it hasn't really moved steadily from one quarter to the next or one year to the next. So we're monitoring it closely, and everyone is aware there's a small surge right now, but based on what we've observed so far, I'd say small is the key word. We're paying close attention, but I don't believe we can project a trend from past data to predict when mortality reaches zero — meaning when excess mortality returns to zero.

Pito Chickering

analyst
#29

All right. Is there any way you could put a number on that for us — for instance, how much excess mortality occurred during this quarter, and what did it look like in the prior quarter?

Joel Ackerman

executive
#30

Sure. In the previous quarter, the figure stood at approximately 900 lives, while for this quarter it came in somewhere in the 500 to 600 range. Keep in mind that these numbers do occasionally get revised down the road. Our visibility into excess mortality improves as more time passes. That said, our current best estimate for Q2 falls within 500 to 600.

Pito Chickering

analyst
#31

Alright. And I completely get the complexity involved in putting those together, for a number of reasons. When it comes to Medicare Advantage, what share of your MA members do you have risk on right now, in some form or another?

Joel Ackerman

executive
#32

I'd need to work that out fast up here. Pito, I don't want to hand you an inaccurate figure. So I'll — let's handle that one separately.

Pito Chickering

analyst
#33

All right. The next item relates to that managed care rate increase inquiry brought up before. I'm wondering, are you observing managed care acting any differently — not only regarding rate hikes, but perhaps in attempts to redirect your patients? For instance, have any shifts in behavior among managed care entities shown up across roughly the past 90 days, particularly given that you're witnessing higher utilization in other areas? I'm just interested whether they're attempting to rein in expenses in other segments of the operation.

Javier Rodriguez

executive
#34

No, nothing has changed whatsoever.

Pito Chickering

analyst
#35

All right, understood. Now, moving to the final item. Regarding how quickly you're consolidating facilities — clearly, you start with the easiest opportunities — but once you're seeing success in bringing those patients into other centers, might you become bolder about consolidation than what you'd initially mapped out for roughly a year from today? Also, once those patients are consolidated, are you observing more home treatments at that stage?

Javier Rodriguez

executive
#36

Yes. I believe we need to be quite cautious about the word "aggressive"; we aim to be very deliberate and balanced regarding every trade-off involved in shutting a center. We must keep in mind that our patients are extremely vulnerable, and one of the most critical considerations is remaining near where they live. That's why 90-some-odd percent of the people we treat live within 10 miles of home. Convenience is among the finest things we're able to provide. We discuss health equity matters a great deal — rather than staying outside communities, we're present within them. So we treat that quite seriously. Still, when economic pressures arise, and provided we can serve our patients, we're handling it very thoughtfully. We also have additional commitments, such as leases and similar matters. So there's a natural point at which to evaluate a clinic and determine whether closing it makes sense. As for the second portion of your question, I think — Pito?

Pito Chickering

analyst
#37

Yes. So <<inaudible>> have posed a number of inquiries in various manners. I suppose, if someone is consolidated, are you observing greater use of treatments administered at home? Then the latter portion of that is, what share of therapies currently take place within the residence?

Javier Rodriguez

executive
#38

The response is no. We aren't detecting any shifts regarding whether someone returns to their residence or not. We remain strongly supportive of the home setting; numerous factors and a good deal of instruction factor into this. We aim for the appropriate approach for each individual, yet we are tremendous proponents of home care. Regarding the proportion for home, it stands at approximately 15%, slightly higher than that, perhaps 15.2% or thereabouts, though it has remained near that 15% mark. COVID exerted a significant influence on home care, as numerous individuals felt more at ease during that period of uncertainty having professionals attend to them, yet we are beginning to notice a modest rise in patients selecting to receive care at home.

Pito Chickering

analyst
#39

All right, and that wraps up my questions, I believe. Could you give us an update on the Medtronic joint venture — how big a drag is it on operating income? And looking at where things stand now, what would the route look like to get it to a point where it's neutral to operating income? Also, could you remind us why you viewed this as such a solid opportunity for your company?

Joel Ackerman

executive
#40

Of course. To begin with, keep in mind that it doesn't affect operating income at all — it sits beneath that line, so the impact lands on EPS. On a pretax basis, it runs roughly $15 million each quarter. That figure is non-GAAP, and during this quarter we actually recorded a positive gain tied to the transaction. We expect that amount to shrink across the coming couple of years, and our expectation was reaching breakeven within two to three years. As for what draws us to this: as Javier noted, we're genuinely focused on finding ways to help patients return home, and new technology can play a role in that solution. We're pursuing additional avenues for innovation past the service and information offerings we already provide, and we see Medtronic as a top-tier innovator in the medical device space. We simply believed that pairing their track record in this area with what we know would create an excellent partnership — that's the reason we put money into Mozarc.

Pito Chickering

analyst
#41

Great, that's fine. Now for my final small item. It's possible I overlooked this. Was any figure given by you folks regarding the turnover rate? Specifically for nurses along with technicians during this quarter, plus what the comparison looks like against 2019?

Javier Rodriguez

executive
#42

I appreciate that closing question. That amount of specificity wasn't provided by us. What I believe we're able to state regarding labor, given that labor has been covered by us in such extensive depth, is that within the broader bucket, things are unfolding the way we anticipated. A few of the elements underneath have moved somewhat. So, to offer slightly more granularity there. Our base wages sit higher than typical averages for us. Contract labor has returned to its usual level, and training remains at an elevated level for us. That's the way those levers are shifting. Still, on the whole, the bucket matches expectations.

Andrew Mok

analyst
#43

I had a few quick follow-ups regarding the shutdowns of clinics. You shut 16 clinics, yet 10 new dialysis clinics were launched. Given that I believed much of the shuttering stemmed from excess mortality, I'm simply attempting to grasp what is now prompting these new openings. So what is it in the marketplace that makes you decide to launch additional clinics? Is there anything distinctive you'd highlight regarding them, such as whether they are home dialysis programs or similar?

Javier Rodriguez

executive
#44

Broadly speaking, as one might expect, the delivery of health care happens locally. Consequently, certain places have clinics that are quite literally at full capacity. Relocations occur at times. Occasionally, as you pointed out, perhaps only a home center was required. So it's a mix of everything. Yet, as is evident, that figure is considerably lower since our emphasis is squarely on ensuring capacity utilization reaches the level it should and on being efficient with capital.

Andrew Mok

analyst
#45

Understood. Regarding the deaths, I believe you provided us with the total count for the quarter. Could you help us understand the overall trend for the mortality rate? And what's the gap versus where things stood before the pandemic?

Javier Rodriguez

executive
#46

The death rate appears to be around one percent above the pre-pandemic baseline; and like Joel mentioned, there's some seasonality to it, varying with surges if any occur, or the pattern tends to be that the earlier part of the year or the later part of the year sees higher mortality compared to the midpoint. But I'd say a solid estimate is approximately 1%, or plus or minus, 2,000 patients.

Javier Rodriguez

executive
#47

Alright, Michelle, thanks — and thanks to everyone for your questions. From what you heard in our remarks today, we've kept pushing on operational efficiencies while putting money into things meant to power results both right now and in the years ahead. A number of the seeds we planted are starting to come up, while others are going to need more time and sustained work; we're eager to keep sharing news about our ongoing progress during the back half of the year. Thanks for being on the call, and take care.

Operator

operator
#48

Thanks. That wraps up the conference call for today. At this point, you're free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.